An upcoming DCAT conference, The DCAT Global Summit 2026: The Future of Bio/Pharma: Mastering the Supply Chain, Digitalization & Global Shifts, June 10-11, in Sitges, Barcelona, Spain, will provide executive perspectives on AI and digital transformation across the bio/pharmaceutical value chain.

Always facing both the risk and rewards of drug development and with greater product complexity, bio/pharmaceutical companies and their suppliers are facing other key challenges and opportunities as digital transformation, including artificial intelligence (AI), emerging technologies, and global manufacturing and supply lines reshape the bio/pharmaceutical value chain.

Bottom line question: How can your company best adapt and be ready for what may lie ahead?  

The DCAT Global Summit 2026: THE FUTURE OF BIO/PHARMA: Mastering the Supply Chain, Digitalization & Global Shifts, a conference and networking event, hosted by the Drug, Chemical & Associated Technologies Association (DCAT), June 10-11, 2026, Sitges, Barcelona, Spain, will feature industry and thought leaders who will share practical insights, first-hand experience, and a vision for the future in responding to these competitive forces. Key highlights include: 

‌Europe at a Crossroads.  

• Market outlook. An in-depth overview of the current and projected performance  of the European bio/pharmaceutical market: Graham Lewis, Vice President, Global Pharma Strategy, IQVIA 

• The EU & Supply Lines:  The latest updates and implications of the Critical Medicines Act, a major policy initiative designed to improve the availability, supply and production of critical medicines within the European Union. Steffen Denzinger, PhD, President, Board of Directors, European Fine Chemicals Group 

AI & Digitalization Keynote: A New Paradigm: Bio/Pharma Digital by Design 
Dr. Christine Allen, CEO & Co-founder, Intrepid Labs Inc., & Professor, University of Toronto 
In this keynote, Dr. Christine Allen, CEO & Co-founder, Intrepid Labs Inc., & Professor, University of Toronto will share a practical vision for the future of bio/pharma: a digital-by-design approach to drug development where experiments, decisions, and supply chains are connected through a modern data backbone. She will explore how AI, high-throughput automation, and cloud-native infrastructure can expand the formulation and process design space while addressing patient experience, manufacturability, cost-per-dose, and supplier resilience globally.   

AI & Digitalization: Advancing Manufacturing 

• AI & Quality by Design (QbD). A practical framework for applying AI in QbD for enhanced product and process understanding. Michael Schorpp, Head of Digital Innovation & AI, Global Regulatory Affairs, Boehringer Ingelheim 

• AI in Process Development & Manufacturing. The use of AI in predictive modeling from early route design through manufacturing. Roman Lagoutte, PhD, Senior Principal Scientist, Lonza; Anil Kane, PhD, Global Head of Technical & Scientific Affairs Pharma Services, Thermo Fisher Scientific; and Juan Piacquadio, DBA, MBA, MSIT, Chief Information Officer & VP IT/IS, Phlow Corp. 

• AI & Biomanufacturing. Application of AI to simulate, analyze, and optimize monoclonal antibody production. Jara Álvarez Aller, Service Delivery Manager and Healthcare Vertical Lead, HP and Timo Liebig, PhD, Chief Innovation Officer, mAbxience  

• AI & Cell-Therapy Manufacturing: Use of advanced AI-driven automation in cell-therapy manufacturing. Yaman Tobaje, Senior Engineer, MSAT, Made Scientific and Rodney Rietze, President & CEO, Streamline Bio  

• AI & Formulation Development. Application of AI in early drug-product development. Christine Allen, CEO & Co-founder, Intrepid Labs Inc. & Professor, University of Toronto and Andrew Lewis, Chief Scientific Officer, Quotient Sciences 

AI & Digitalization: The Supply Chain  

AI & Supply Chain Resilience. Case examples of applying automation, AI, and digital solutions to improve efficiency, compliance, and supply chain resilience. Thomas Altmann, Principal Global Technical Consultant, Ecolab Deutschland GmbH and Clemente Aguila, Head of Operations & Corporate Procurement, Grifols 

AI & Risk Mitigation. Perspectives from industry leaders on developing smarter partnerships, AI-enabled procurement, and data-driven decision-making to mitigate risk and build resilience. Gijs Vissers, Head of Supply and Procurement, Nordic Pharma; Priya Kumar, Founder & CEO, Sustainable Inc.; Abhay Bhutkar, Director, Strategic Accounts, QYOBO; and Jagruti Patel, Sr. Director, Commercial Development Integrated Biologics EMEA/AP, Lonza 

AI & Digitalization: Human Capital and Talent Development 
AI & Workforce Enablement. Key learnings on how to achieve smarter AI-driven governance, apply modern digital learning models, and establish scalable workforce development strategies. Sigma Mostafa, PhD, Chief Scientific Officer, KBI Biopharma and Coral Buter, Group Head of Digitally Enabled Lean Project Delivery, PM Group 

AI Executive Workshop 
Dr. Ayesha Khanna, a global AI expert, recognized as a groundbreaking entrepreneur by Forbes, and CEO of Addo, a strategic consulting firm advising businesses how to leverage AI for growth.  

This workshop will equip senior leaders with actionable insights to apply AI to drive efficiency and competitive advantage in the proposal process while providing a strategic understanding of agentic AI—autonomous, scalable systems that redefine how enterprises operate at scale. Attendees will gain a forward-looking perspective on the trajectory of AI to faciliate executive decision-makers to anticipate disruption, align organizational strategy, and position their enterprises at the forefront of AI-driven transformation. 

Further information, including how to register, may be found here. The event is open to both DCAT Member Companies and non-DCAT Member Companies